Effect of methotrexate treatment for ectopic pregnancy on current and subsequent pregnancy

Shirin Namouz-Haddad; Gideon Koren

doi:10.1007/978-3-319-11140-7_10

Effect of methotrexate treatment for ectopic pregnancy on current and subsequent pregnancy

Shirin Namouz-Haddad, Gideon Koren

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.

Original language	English
Title of host publication	Ectopic Pregnancy
Subtitle of host publication	A Clinical Casebook
Pages	69-75
Number of pages	7
ISBN (Electronic)	9783319111407
DOIs	https://doi.org/10.1007/978-3-319-11140-7_10
State	Published - 1 Jan 2015
Externally published	Yes

Keywords

Aminopterin syndrome
Methotrexate embryopathy
Methotrexate toxicity
Teratogen

Access to Document

10.1007/978-3-319-11140-7_10

Cite this

@inbook{ea8574167cab4b3faf689b7e0edbc160,

title = "Effect of methotrexate treatment for ectopic pregnancy on current and subsequent pregnancy",

abstract = "Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.",

keywords = "Aminopterin syndrome, Methotrexate embryopathy, Methotrexate toxicity, Teratogen",

author = "Shirin Namouz-Haddad and Gideon Koren",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-11140-7\_10",

language = "אנגלית",

isbn = "9783319111391",

pages = "69--75",

booktitle = "Ectopic Pregnancy",

}

TY - CHAP

T1 - Effect of methotrexate treatment for ectopic pregnancy on current and subsequent pregnancy

AU - Namouz-Haddad, Shirin

AU - Koren, Gideon

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.

AB - Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.

KW - Aminopterin syndrome

KW - Methotrexate embryopathy

KW - Methotrexate toxicity

KW - Teratogen

UR - https://www.scopus.com/pages/publications/84944618182

U2 - 10.1007/978-3-319-11140-7_10

DO - 10.1007/978-3-319-11140-7_10

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84944618182

SN - 9783319111391

SP - 69

EP - 75

BT - Ectopic Pregnancy

ER -

Effect of methotrexate treatment for ectopic pregnancy on current and subsequent pregnancy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this